HCV infection is a major cause of mortality worldwide. HCV-related deaths also represent a leading cause of mortality in HIV-coinfected individuals. Telaprevir is an NS3/4A protease inhibitor approved for the treatment of chronic HCV genotype 1 infection in adults in combination with pegylated interferon and ribavirin. Telaprevir-based treatment has been shown to increase rates of sustained viral response in HCV genotype-1-monoinfected patients, and studies in HCV–HIV-coinfected patients are ongoing. Drug–drug interactions of telaprevir with antiretroviral drugs were investigated in a series of studies in healthy subjects. This review summarizes the results of interaction studies with low-dose ritonavir, ritonavir-boosted HIV protease inhibitors (atazanavir, darunavir, fosamprenavir and lopinavir), efavirenz, etravirine, rilpivirine, tenofovir disoproxil fumarate and raltegravir.
References
1.
De FrancescoR., MigliaccioG.Challenges and successes in developing new therapies for hepatitis C. Nature2005; 436: 953–960.
2.
BrownR.S.Jr., GaglioP.J.Scope of worldwide hepatitis C problem. Liver Transpl2003; 9: S10–S13.
3.
WasleyA., AlterM.J.Epidemiology of hepatitis C: geographic differences and temporal trends. Semin Liver Dis2000; 20: 1–16.
4.
AlterH.J., SeeffL.B.Recovery, persistence, and sequelae in hepatitis C virus infection: a perspective on long-term outcome. Semin Liver Dis2000; 20: 17–35.
5.
AlterM.J.Epidemiology of viral hepatitis and HIV co-infection. J Hepatol2006; 44: S6–S9.
6.
ChenT.Y., DingE.L., SeageG.R., KimA.Y.Meta-analysis: increased mortality associated with hepatitis C in HIV-infected person is unrelated to HIV disease progression. Clin Infect Dis2009; 49: 1605–1615.
7.
d'Arminio MonforteA., Cozzi-LepriA., CastagnaA.Risk of developing specific AIDS defining illnesses in patients co-infected with HIV and hepatitis C virus with or without liver cirrhosis. Clin Infect Dis2009; 49: 612–622.
8.
KovaczA., KarimR., MackW.J.Activation of CD8 T cells predicts progression of HIV infection in women coinfected with hepatitis C virus. J Infect Dis2010; 201: 823–834.
9.
Panel on Antiretroviral Guidelines for Adults and Adolescents.Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents.Department of Health and Human Services. 10 January 2011; pp. 1–166.
10.
TheinH.H., YiQ., DoreG.J., KrahnM.D.Natural history of hepatitis C virus infection in HIV infected individuals and the impact of HIV in the era of the highly active antiretroviral therapy: a meta-analysis. AIDS2008; 22: 1979–1991.
11.
ShireN.J., WelgeJ.A., ShermanK.E.Response rates to pegylated interferon and ribavirin in HCV/HIV coinfection: a research synthesis. J Viral Hepat2007; 14: 239–248.
LinC., KwongA.D., PerniR.B.Discovery and development of VX-950, a novel, covalent, and reversible inhibitor of hepatitis C virus NS3.4A serine protease. Infect Disord Drug Targets2006; 6: 3–16.
15.
GargV., KauffmanR.S., BeaumontM., van HeeswijkR.P.G.Telaprevir: pharmacokinetics and drug interactions. Antivir Ther; 2012; 17: 1211–1221.
16.
GargV., ChandorkarG., FarmerH.F., SmithF., AlvesK., van HeeswijkR.P.Effect of telaprevir on the pharmacokinetics of midazolam and digoxin. J Clin Pharmacol2012; 52: 1566–1573.
17.
ZeuzemS., AndreoneP., PolS.Telaprevir for retreatment of HCV infection. N Engl J Med2011; 364: 2417–2428.
18.
JacobsonI.M., McHutchisonJ.G., DusheikoG.M.Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med2011; 364: 2405–2416.
19.
ShermanK.E., FlammS.L., AfdhalN.H.Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med2011; 365: 1014–1024.
GargV., LuoX., McNairL., van HeeswijkR., KauffmanR.S.The effect of low-dose ritonavir on the pharmacokinetics of the investigational HCV protease inhibitor telaprevir in healthy volunteers.18th Conference on Retroviruses and Opportunistic Infections. 27 February–2 March 2011, Boston, MA, USA. Abstract 629.
CvetkovicR.S., GoaK.L.Lopinavir/ritonavir: a review of its use in the management of HIV infection. Drugs2003; 63: 769–802.
24.
Van HeeswijkR., VandevoordeA., BoogaertsG.Pharmacokinetic interactions between ARV agents and the investigational HCV protease inhibitor TVR in healthy volunteers.18th Conference on Retroviruses and Opportunistic Infections. 27 February–2 March 2011, Boston, MA, USA. Abstract 19.
HulskotteE., FengH.P., XuanF.Pharmacokinetic interaction between the HCV protease inhibitor boceprevir and ritonavir-boosted HIV-1 protease inhibitors atazanavir, lopinavir and darunavir.19th Conference on Retroviruses and Opportunistic Infections. 5–8 March 2012, Seattle, WA, USA, 2012. Abstract 77ILB.
27.
Van HeeswijkR., VandevoordeA., VerbovenP.The pharmacokinetic interaction between methadone and the investigational HCV protease inhibitor telaprevir.European Association for the Study of the Liver. 30 March–3 April 2011, Berlin, Germany. Abstract 1244.
28.
ChakilamA., ChavanA., SmithG., Lachau-DurandS., GargV.Telaprevir binding to isolated human plasma proteins and protein binding displacement interactions between telaprevir and ritonavir or warfarin. Rev Antiviral Ther Infectious Dis2011; 6: 22.
29.
BoffitoM., BackD.J., BlaschkeT.F.Protein binding in antiretroviral therapies. AIDS Res Hum Retroviruses2003; 19: 825–835.
30.
SadlerB.M., GillotinC., LouY., SteinD.S.In vivo effect of a1-acid glycoprotein on pharmacokinetics of amprenavir, a human immunodeficiency virus protease inhibitor. Antimicrob Agents Chemother2001; 45: 852–856.
31.
RittwegerM., ArastéhK.Clinical pharmacokinetics of darunavir. Clin Pharmacokinet2007; 46: 739–756.
32.
Barrail-TranA., MentreF., CossonC.Influence of alpha-1 glycoprotein acid concentrations and variants on atazanavir pharmacokinetics in HIV-infected patients included in the ANRS 107 study. Antimicrob Agents Chemother2010; 54: 614–619.
33.
TongL., PhanT.K., RobinsonK.L.Effects of human immunodeficiency virus protease inhibitors on the intestinal absorption of tenofovir disoproxil fumarate in vitro. Antimicrob Agents Chemother2007; 51: 3498–3504.
Van HeeswijkR., GysenV., BoogaertsG.The pharmacokinetic interaction between tenofovir disoproxil fumarate and the investigational HCV protease inhibitor telaprevir.Interscience Conference on Antimicrobial Agents and Chemotherapy. 25 October 2008, Washington, DC, USA. Abstract A-966.
36.
RayA.S., CihlarT., RobinsonK.L.Mechanism of active tubular efflux of tenofovir. Antimicrob Agents Chemother2006; 50: 3297–3304.
GargV., ChandorkarG., YangY.The effect of CYP3A inhibitors and inducers on the pharmacokinetics of telaprevir in healthy volunteers. Br J Clin Pharmacol2013; 75: 431–439.
39.
KakudaT.N., Schöller GyüreM., HoetelmansR.M.Pharmacokinetic interactions between etravirine and non-antiretroviral drugs. Clin Pharmacokinet2011; 50: 25–39.
40.
KakudaT.N., LeopoldL., NijsS.Pharmacokinetic interaction between etravirine or rilpivirine and telaprevir in healthy volunteers: a randomised, two-way crossover trial.13th International Workshop on Clinical Pharmacology of HIV. 16–18 April 2012, Barcelona, Spain. Abstract 0_18.
41.
CrauwelsH., VingerhoetsJ., RyianR., WitekJ., AndersonD.Pharmacokinetic parameters of once-daily rilpivirine following administration of efavirenz in healthy subjects. Antivir Ther2012; 17: 439–446.
42.
VanveggelS., BuelensA., CrauwelsH.M.TMC278 25mg once daily has no effect on corrected QT interval in a study in HIV-negative volunteers.12th European AIDS Clinical Society. 11–14 November 2009, Cologne, Germany. Abstract PE7.1/2.
43.
Van HeeswijkR., GargV., BoogaertsG.The pharmacokinetic interaction between telaprevir and raltegravir in healthy volunteers.51st Interscience Conference on Antimicrobial Agents and Chemotherapy. 17 September 2011, Chicago, IL, USA. Abstract 1738a.
44.
DietrichD.T., SorianoV., ShermanK.E.Telaprevir in combination with peginterferon alfa-2a/ribavirin in HCV/HIV coinfected patients: a 24-week treatment interim analysis.19th Conference on Retroviruses and Opportunistic Infections. 5–8 March 2012, Seattle, WA, USA. Abstract 46.
